Xcout Intel
Mana.bio
Mana.bio is an AI-based drug delivery startup headquartered in Tel Aviv, Israel, focusing on gene therapy and lipid nanoparticle development for mRNA and oligonucleotide therapeutics. The company leverages artificial intelligence to create advanced platforms for next-generation vaccines and genetic medicines.
Subscribe to see Mana.bio’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Mana.bio at a glance
Mana.bio is a drug delivery company headquartered in Israel, founded in 2021. Its most recent funding round, Seed, raised $19.5M in October 2023. Xcout tracks 4 named people at Mana.bio, including Yogev Debbi (Co-Founder & CEO).
Mana.bio leadership
- Yogev DebbiCo-Founder & CEO
- Roy NevoCo-Founder & CTO
- Dr. Kira RadinskyScientific co-founder
- Prof. Avi SchroederScientific co-founder
Mana.bio funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $19.5M | 4 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Mana.bio competitors
A few of Mana.bio's closest competitors — see the full list of competitors and alternatives →
Cassidy Bio is an AI-first biotechnology company founded in 2024 and based in Israel that is developing a programmable platform for gene editing. The company utilizes a genomic foundation model powered by artificial intelligence to design safer and more scalable gene editing therapies across various guides, editors, and delivery contexts.
Cellyrix Therapeutics is an Israeli biotechnology company that develops targeted cancer therapies by leveraging single-cell RNA sequencing and artificial intelligence. The firm operates as an oncology-focused drug discovery venture headquartered in Rehovot, Israel.
Generare is a biotechnology and artificial intelligence company headquartered in Paris, France, focused on commercial bioprospecting and decoding natural products.
Variational AI is a privately held biotechnology startup headquartered in Vancouver, British Columbia. Founded in 2019, the company focuses on drug discovery, utilizing artificial intelligence to identify novel drug-like small molecules. Recognized as an innovative AI enterprise in Canada, it develops advanced computational methods for pharmaceutical research.
Renasis Bio Ltd. is a stealth-mode private company headquartered in Rehovot, Israel, established in 2025. The firm is developing an AI-driven drug discovery platform focused on RNA-targeting small molecules to advance RNA druggability.
Promise Bio is a biotechnology research startup transforming immune-mediated disease treatment with advanced precision therapies. Headquartered in Tel Aviv, Israel, the company emerged from stealth following a seed investment.
Get Mana.bio's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Mana.bio in Xcout Intel
- 4 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access